The Potential of Isoniazid Derivatives as Anti-Tuberculosis Drugs targeting 6MA8: In Silico Study
Open Access
- 4 June 2025
- journal article
- Published by Universitas Pakuan in Helium: Journal of Science and Applied Chemistry
- Vol. 5 (1) , 38-44
Abstract
Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis. Isoniazid, a synthetic antimicrobial agent, remains one of the most crucial first-line medications in TB therapy. Enhancing TB treatment strategies can be achieved through structural modifications of existing drugs. This study investigates the potential of isoniazid derivatives as anti-tuberculosis agents targeting the CYP3A4 protein complexed with a small-molecule inhibitor (PDB ID: 6MA8) and evaluates their toxicity profiles using in silico methods. The ligands analyzed include isoniazid derivatives 1–5, with isoniazid as a reference compound and protoporphyrin as the native ligand. The structure of ligands was prepared using Avogadro software and optimized with ORCA software. The crystal structures of 6MA8 were retrieved from the PDB database and further validated using YASARA. In silico methods such as molecular docking and ProTox prediction were employed to evaluate the potential of these isoniazid derivatives as anti-TB drugs. The interactions were visualized using Biovia Discovery to assess the interaction between the isoniazid derivatives and the receptor. The results showed derivative 4 exhibited the lowest binding affinity (-71.56 kcal/mol) compared to isoniazid (-65.90 kcal/mol), derivative 1 (-63.65 kcal/mol), derivative 2 (-67.01 kcal/mol), derivative 3 (-67.37 kcal/mol), derivative 5 (-69.02 kcal/mol), and native ligand (-182.68 kcal/mol). Biovia Discovery Studio simulations indicated that the isoniazid derivatives interacted with 6MA8 via conventional hydrogen bonds, carbon-hydrogen bonds, and other interactions. The toxicity analysis showed that the derivatives had safe LD50 values, supporting their safety profiles. These results suggest that isoniazid derivatives have promising potential as anti-tuberculosis agents targeting 6MA8.Keywords
This publication has 15 references indexed in Scilit:
- Docking and molecular dynamic study of isoniazid derivatives as anti-tuberculosis drug candidateChemical Data Collections, 2021
- A systemic review on tuberculosisIndian Journal of Tuberculosis, 2020
- Multi-Drug Resistant and Extensively-Drug Resistant TuberculosisIndian Journal of Pediatrics, 2020
- Interaction of Human Drug-Metabolizing CYP3A4 with Small Inhibitory MoleculesBiochemistry, 2019
- Isoniazid derivatives and their anti-tubercular activityEuropean Journal of Medicinal Chemistry, 2017
- Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2017
- Isoniazid: A Review of Characteristics, Properties and Analytical MethodsCritical Reviews in Analytical Chemistry, 2016
- Tuberculosis treatment and management—an update on treatment regimens, trials, new drugs, and adjunct therapiesThe Lancet Respiratory Medicine, 2015
- Toxicity Testing in the 21st Century: A Vision and a StrategyJournal of Toxicology and Environmental Health, Part B, 2010
- Mechanisms of mycobacterial persistence in tuberculosisClinical Immunology, 2005